Navigation Links
Z Trim Holdings Reports Restatement of Previously Issued Financial Statements; Amends Bylaws
Date:11/1/2007

the Shemesh/Tobian Shares. Through that date, the Company had recognized $765,324.75 of expense relating to the contract. Accordingly, at September 30, 2005 the Company wrote off the remaining $1,012,175.25 against paid-in-capital.

Shemesh and Tobian disputed the Company's basis for rescinding the contract and because they were referred to the Company by Farhad Zaghi, the Company's purported rescission became an issue in the Company's ongoing litigation with Zaghi and his affiliates. In order to eliminate one of the issues of contention between the parties and facilitate further settlement negotiations with Zaghi, on March 9, 2007, the Company released the stop order on the Shemesh/Tobian Shares and allowed the shares to be traded. Because the Company previously had recorded a write-off against paid-in-capital associated with the Shemesh/Tobian Shares, upon lifting the stop order the Company should have re-expensed the Shemesh/Tobian Shares.

Expected Impact of the Restatement.

The Company will recognize an expense to investor relations of $1,012,175.25 as of March 9, 2007 and will restate its financial statements for the quarters ended March 31, 2007 and June 30, 2007 accordingly. As a result of this additional expense, the Company will realize an additional loss of $0.02 per share for the quarter ended March 31 (for a total loss per share of $0.04 for that period) and an additional loss of $0.02 per share for the six months ended June 30 (for a total loss per share of $0.08 for that period). The Company intends to amend its Quarterly Reports on Form 10-Q for the applicable periods prior to filing its third quarter 10-Q on or prior to November 19, 2007.

Additional Restatements Possible.

On August 23, 2007, the Company announced it was conducting an audit of certain accounting and financial reporting practices in connection with the Company's receipt of a deficiency letter from the American Stock Exchange. That audit is not complete and
'/>"/>

SOURCE Z Trim Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... are higher than generally thought, raising concerns about increased risk for ... California, San Francisco (UCSF) imaging specialists. , ... ... common CT procedures vary widely and are higher than generally thought, ... study led by University of California, San Francisco (UCSF) ...
(Date:12/14/2009)... Tide of Tens of Thousands of New Chronic ... Legislation approved by Congress providing for ... in helping to reduce tens of thousands of ... the United States, the National Viral Hepatitis ... was included in the FY 2010 Consolidated Appropriations ...
(Date:12/14/2009)... 2009, the United States Court of Appeals, Tenth Circuit, ... are "plans" and therefore subject to federal jurisdiction. (US ... that contracts issued by insurance companies may be subject ... US vs. Frost is the first case an ... "plan," because, as the government claimed in this case, ...
(Date:12/14/2009)... linked to scans performed in 2007 , , MONDAY, Dec. ... patients to far more radiation than previously thought and in ... year, two new studies claim. , Based on the findings, ... of Internal Medicine , the study authors, joined by ... clinicians to limit radiation exposure to patients. , "CT has ...
(Date:12/14/2009)... of scientists from the UC San Diego School of ... protein switch that helps prevent liver damage, including inflammation, ... understanding of how the protein, TAK1, works could lead ... and cancer. , "TAK1 appears to be a ... MD, professor of medicine and Dean of the UC ...
Breaking Medicine News(10 mins):Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2Health News:Insurance Now Subject to Federal Jurisdiction 2Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4Health News:Scientists uncover protective mechanism against liver cancer 2
... characterization of renal transplant patients being weaned ... ... Data developed by Cylex in,conjunction with the University of Pittsburgh ... Canada, suggest,that cell-mediated immunity and anti-HLA antibody assays may be independent,measures ...
... For the past 70 years the treatment of ... therapy. That is, the suppression of circulating testosterone ... castration (orchiectomy) or medical castration with testosterone-blocking drugs. While ... a cure, as inevitably the cancer becomes resistant to ...
... time with pancreatic, kidney cancers, respectively , , ... with pancreatic cancer -- which historically carries a ... when the cancer drug Gemzar was used after ... 15 percent of pancreatic cancer patients are even ...
... progression-free survival, study finds , , SATURDAY, May 31 ... chemotherapy lengthened progression-free survival in women with advanced ... have found that adding Avastin (bevacizumab) to the ... breast cancer actually doubled progression-free survival. , Avastin ...
... likely to have diminished ovarian reserve producing viable ... News) -- Chemotherapy may reduce fertility in breast ... researchers at Boston,s Dana-Farber Cancer Institute. , They ... chemotherapy following surgery were more likely than women ...
... and cold medication use in young children has been ... several deaths, leading the FDA to recommend against their ... these concerns about safety and efficacy, there has been ... use in very young children. Now, a new study ...
Other Medicine News:Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 2Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 3Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 2Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 3Health News:New Hope for Tough-to-Treat Cancers 2Health News:New Hope for Tough-to-Treat Cancers 3Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 3Health News:Chemo May Limit Fertility in Breast Cancer Survivors 2Health News:Study examines cold medication use in young children 2
(Date:12/14/2009)... 14 In response to an ... in which the Agency recommended that healthcare facilities ... sterile processing system, hospitals throughout the U.S. are ... to that product. According to the FDA, STERIS ... that may affect the safety or the effectiveness ...
(Date:12/14/2009)... -- Following is a statement by Linda A. ... Association (CHPA), regarding today,s release of the National ... survey: ,, "Findings released today on this year,s ... for continued efforts to educate and empower parents ... their teens about medicine abuse. The Consumer Healthcare ...
(Date:12/14/2009)... The board of directors of Eli Lilly ... a dividend for the first quarter of 2010 of ... ,, The dividend is payable March 10, 2010 to ... ,, February 12, 2010. ,, Lilly, a leading ... products by applying the latest research from its own ...
Breaking Medicine Technology:ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 2ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 3Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 2Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 3Carnegie Mellons Jean VanBriesen leads research team on Monongahela River 9506 1Carnegie Mellons Jean VanBriesen leads research team on Monongahela River 9506 2Protein handlers should be effective treatment target for cancer and Alzheimers 9501 1Protein handlers should be effective treatment target for cancer and Alzheimers 9501 2Protein handlers should be effective treatment target for cancer and Alzheimers 9501 3America Takes on the Challenge to Fight Obesity 53865 1America Takes on the Challenge to Fight Obesity 53865 2America Takes on the Challenge to Fight Obesity 53865 3America Takes on the Challenge to Fight Obesity 53865 4
... lowest dose groups show dose-dependent PSA ... declines to date in all patients - - ... SAN FRANCISCO, Nov. 5 Medivation, Inc.,(Nasdaq: MDVN ) today ... levels of prostate specific,antigen (PSA), a marker of tumor growth, in the ...
... non-responders to previous interferon-based therapy -, - SVR results in ... non- responders, with less frequent dosing -, - ... American Association for the Study of Liver Diseases ... (AASLD) -, ROCKVILLE, Ma., Nov. 5 ...
Other Medicine Technology:Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 2Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 3Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6
Round knurled handle. Overall length 130 mm....
Hosford foreign body spud 4 3/4 inches, gouge blade 1 x 7 mm rounded tip, angled to left....
DIX foreign body spud 4 3/4 inches, 1.7 x 15 mm blade....
Foreign body spud very thin, lightly curved and rounded tip....
Medicine Products: